{{Rsnum
|rsid=1414334
|Gene=HTR2C
|Chromosome=X
|position=114903581
|Orientation=plus
|GMAF=0.1856
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=HTR2C
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 8.9 | 15.2 | 75.9
| HCB | 2.2 | 0.7 | 97.1
| JPT | 1.8 | 2.7 | 95.6
| YRI | 43.4 | 22.8 | 33.8
| ASW | 28.1 | 33.3 | 38.6
| CHB | 2.2 | 0.7 | 97.1
| CHD | 0.0 | 1.8 | 98.2
| GIH | 7.9 | 4.0 | 88.1
| LWK | 35.8 | 27.5 | 36.7
| MEX | 7.0 | 5.3 | 87.7
| MKK | 22.6 | 24.5 | 52.9
| TSI | 13.1 | 11.1 | 75.8
| HapMapRevision=28
}}
{{PMID|19142101}} rs1414334(C) associated with the metabolic syndrome in patients using 
*[[clozapine]] (OR, 9.20; 95% CI, 1.95-43.45)
*[[risperidone]] (OR, 5.35; 95% CI, 1.26-22.83)

{{PharmGKB
|RSID=rs1414334
|Name_s=
|Gene_s=HTR2C
|Feature=
|Evidence=PubMed ID:20680028
|Annotation=Risk or phenotype-associated allele: C. Phenotype: In a replication study, the C allele of HTR2C rs1414334 polymorphism is associated with development of the metabolic syndrome during treatment with antipsychotics. Study size: 186. Study population/ethnicity: 93% Caucasian; European; Dutch; The Netherlands. Significance metric(s): OR = 3.73; 95% CI= 1.29-10.79; P = 0.015. Type of association: CO.
|Drugs=
|Drug Classes=ANTIPSYCHOTICS
|Diseases=Metabolic Syndrome X
|Curation Level=Curated
|PharmGKB Accession ID=PA165374493
}}

{{PMID Auto
|PMID=20680028
|Title=Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study
}}

{{PharmGKB
|RSID=rs1414334
|Name_s=
|Gene_s=HTR2C
|Feature=
|Evidence=PubMed ID:19142101
|Annotation=In a pooled analysis of two studies the variant C allele was specifically associated with the metabolic syndrome in patients using clozapine or risperidone.
|Drugs=clozapine; risperidone
|Drug Classes=
|Diseases=metabolic syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162370423
}}
{{PMID Auto
|PMID=21186965
|Title=Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene
|OA=1
}}

{{PMID Auto
|PMID=21105285
|Title=Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication
}}

{{PMID Auto
|PMID=17016522
|Title=The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study.
}}

{{PMID Auto
|PMID=17632216
|Title=The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1414334
|overall_frequency_n=61
|overall_frequency_d=92
|overall_frequency=0.663043
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=68
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}